Showing results (1-10 of 40) with videos related to
Sort By:
Pageof 4
Current Pharmaceutical Design|February 26, 2011
Promotion of apoptosis in cancer cells by selective purine-derived pharmacological CDK inhibitors: one outcome, many mechanismsJózefa Węsierska-Gądek, Margarita MaurerAnnals of the New York Academy of Sciences|September 3, 2009
Roscovitine differentially affects asynchronously growing and synchronized human MCF-7 breast cancer cellsMargarita Maurer, Oxana Komina, Józefa Wesierska-GadekJournal of Cellular Biochemistry|April 7, 2007
Inhibition of farnesyl protein transferase sensitizes human MCF-7 breast cancer cells to roscovitine-mediated cell cycle arrestJózefa Wesierska-Gadek, Margarita Maurer, Gerald SchmidJournal of Experimental Therapeutics & Oncology|February 1, 2011
Effect of anti-estrogen combined with roscovitine, a selective CDK inhibitor, on human breast cancer cells differing in expression of ERNora Zulehner, Margarita Maurer, Józefa Wesierska-GadekFood and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|October 16, 2007
Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cellsJózefa Wesierska-Gadek, Matthias P Kramer, Margarita MaurerActa Biochimica Polonica|September 3, 2009
Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potentialJózefa Wesierska-Gadek, Andreea Borza, Oxana Komina, et al.Journal of Experimental Therapeutics & Oncology|February 1, 2011
Tamoxifen enhances the anti-proliferative effect of roscovitine, a selective cyclin-dependent kinase inhibitor, on human ER-positive human breast cancer cellsDavid Gritsch, Margarita Maurer, Nora Zulehner, et al.Journal of Cellular Physiology|September 14, 2010
Whether to target single or multiple CDKs for therapy? That is the questionJózefa Węsierska-Gądek, Margarita Maurer, Nora Zulehner, et al.Journal of Experimental Therapeutics & Oncology|February 1, 2011
Triazoloacridone C-1305 abrogates the restriction checkpoint in cells lacking functional p53 and promotes their accumulation in the G2/M phase of the cell cycleMargarita Maurer, Oxana Komina, Andrzej Składanowski, et al.Oncoimmunology|December 18, 2012
Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approachesMargarita Maurer, Rajasekharan Somasundaram, Meenhard Herlyn, et al.Pageof 4